Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
Managing patients who experience 15 or more headache days per month requires effective evidence-based strategies. A recent systematic review evaluates several chronic migraine prophylaxis medications to determine their clinical efficacy and patient tolerability. This extensive review synthesized data from 43 randomized controlled trials involving over 14,000 participants.
The study found that CGRP-targeted therapies, including eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant, significantly reduce monthly migraine days. Specifically, these agents reduced migraine frequency by approximately two days compared to placebo. Conversely, researchers noted that rimegepant probably has no effect on preventing chronic migraine, despite its utility in other settings.
Furthermore, the certainty of evidence for these newer therapies is generally high to moderate. While botulinum toxin slightly reduces monthly headache days, it also carries a higher risk of discontinuation due to adverse events. Consequently, clinicians must balance potential relief with the likelihood of treatment adherence. Additionally, evidence for older medications like topiramate, valproate, and propranolol remains limited for chronic cases. Most studies on these older agents carried a high risk of bias. Therefore, CGRP-targeted biologics currently offer a more reliable evidence base for patients with frequent attacks.
When selecting a therapy, physicians should consider individual patient profiles and the risk of dropout. For instance, galcanezumab may actually reduce all-cause dropout rates compared to placebo. However, traditional oral preventatives still play a role in certain clinical scenarios despite the data gaps identified in this review. Most calcitonin gene-related peptide-targeted therapies are probably effective, marking a significant advancement in chronic migraine management.
According to high-certainty evidence, CGRP-targeted therapies such as erenumab, eptinezumab, and atogepant are among the most effective for reducing monthly migraine days in adults.
While botulinum toxin provides some reduction in headache days, the review suggests it may lead to more frequent discontinuation due to side effects compared to newer CGRP-targeted options.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
New research evaluates the efficacy of CGRP-targeted therapies, botulinum toxin, and oral medications for chronic migraine prophylaxis in adults....
last month
A multicohort study across 33 countries reveals that loneliness significantly increases the risk of cardiometabolic disease, particularly multimorbidity. The study highlights the synergistic impact of unhealthy lifestyles and low socioeconomic status on cardiovascular health in aging populations.
Today
A study on 294 women after the Kahramanmaras earthquake shows that death distress, especially death depression, significantly influences fertility intentions. Key factors include age, income, and trauma experience, highlighting the need for mental health support in post-disaster care.
Today
Recent research highlights mussel-inspired catechol-amine copolyether brushes as a breakthrough in antifouling. By achieving high grafting density and maintaining chemical integrity, these coatings effectively prevent biofilm formation on medical devices, offering a substrate-independent solution for clinicians.
Today
A randomized controlled trial compared static stretching and myofascial release for hamstring tightness in IT professionals. While both methods improved flexibility, myofascial release demonstrated superior results in range of motion and functional scores over a three-week treatment period.
Today
Recent research identifies miR-335-5p as a key regulator for redifferentiating BRAF-mutant thyroid cancers. Restoring this microRNA enhances iodine uptake and inhibits EMT pathways, potentially resensitizing tumors to radioiodine and improving kinase inhibitor outcomes for refractory patients.
Today